Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome

Br J Ophthalmol. 2007 Feb;91(2):263-4. doi: 10.1136/bjo.2006.0101477.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Child, Preschool
  • Etanercept
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Inflammation / drug therapy
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Joint Diseases / drug therapy
  • Male
  • Methotrexate / therapeutic use
  • Methylprednisolone / therapeutic use
  • Prednisolone / therapeutic use
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Syndrome
  • Uveitis, Posterior / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Tumor Necrosis Factor
  • Prednisolone
  • Etanercept
  • Methylprednisolone
  • Methotrexate